Amundi’s United Therapeutics UTHR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$87.5M Sell
147,599
-15,595
-10% -$7.77M 0.02% 480
2025
Q4
$79.5M Buy
163,194
+33,209
+26% +$15.5M 0.02% 535
2025
Q3
$58.9M Sell
129,985
-232,841
-64% -$78.3M 0.02% 523
2025
Q2
$107M Buy
362,826
+12,633
+4% +$3.78M 0.04% 399
2025
Q1
$108M Buy
350,193
+232,988
+199% +$79.8M 0.04% 384
2024
Q4
$43M Buy
117,205
+51,885
+79% +$19.1M 0.01% 587
2024
Q3
$23.2M Sell
65,320
-407,672
-86% -$138M 0.01% 687
2024
Q2
$147M Buy
472,992
+307,962
+187% +$81.5M 0.06% 292
2024
Q1
$39.1M Sell
165,030
-24,434
-13% -$5.51M 0.02% 574
2023
Q4
$42.5M Buy
189,464
+48,150
+34% +$11.1M 0.02% 566
2023
Q3
$32.9M Buy
141,314
+87,931
+165% +$20.3M 0.02% 600
2023
Q2
$11.9M Buy
53,383
+28,161
+112% +$6.24M 0.01% 806
2023
Q1
$5.88M Sell
25,222
-4,471
-15% -$1.1M ﹤0.01% 962
2022
Q4
$7.83M Buy
29,693
+28,146
+1,819% +$7.11M ﹤0.01% 904
2022
Q3
$328K Buy
1,547
+18
+1% +$4.02K ﹤0.01% 1402
2022
Q2
$363K Sell
1,529
-204
-12% -$41.5K ﹤0.01% 1304
2022
Q1
$329K Sell
1,733
-147
-8% -$28K ﹤0.01% 1332
2021
Q4
$391K Hold
1,880
﹤0.01% 1419
2021
Q3
$347K Hold
1,880
﹤0.01% 1390
2021
Q2
$337K Buy
+1,880
New +$358K ﹤0.01% 1308

Other funds holding UTHR

Amundi's UTHR Position: Q1 2026 in Review

Amundi reduced its United Therapeutics (UTHR) stake by 9.6% in Q1 2026, selling an estimated $7.77M and leaving 147,599 shares worth $87.5M. The position accounts for 0.02% of the portfolio, ranked #480.

Amundi first reported a position in UTHR in Q2 2021 and has held it in 20 quarters since. The position peaked at $147M in Q2 2024. 850 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

  • Amundi held 147,599 shares of United Therapeutics worth $87.5M as of Q1 2026.
  • Amundi sold 15,595 United Therapeutics shares in Q1 2026, an estimated $7.77M.
  • United Therapeutics made up 0.02% of Amundi's portfolio in Q1 2026, its #480 holding.
  • Amundi first reported a position in United Therapeutics in Q2 2021 and has held it in 20 quarters since.
  • Amundi's United Therapeutics position peaked at $147M in Q2 2024.
  • 850 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on Amundi's 13F filing for Q1 2026, filed 18 May 2026.